Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in children with enthesitis-related arthritis and juvenile psoriatic arthritis
NL-OMON60066Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ixekizumab in juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), juvenile psoriatic arthritis (JPsA) and ankylosing spondylitis (AS), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of participants achieving JIA ACR30. Started Sep 2021; status: completed.
02
Drugs
ixekizumab
03
Conditions
juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)juvenile psoriatic arthritis (JPsA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON60066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60066.